

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham
Vice President for Research

October 2021

Attachment A

Project #1

Amendment to Research Agreement between the University and Ascentage Pharma Group Corporation, Ltd. Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination with Systemic Anti-Cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies Budget Amendment #1	U-M Project ID: 22-PAF02241
Direct Sponsor: Ascentage Pharma Group Corporation, Ltd.	
Principal Investigator/Department: Paul Swiecicki, Internal Medicine-Hematology/Oncology	
Agreement Initiated: N/A	
Current Project Duration: Five (5) Years Additional Time: N/A	Current Funding Support: \$990,384 Additional Funding Support: \$318,197
Purpose: The purpose of this amendment to correct the original budget amount adding funds so that Dr. Swiecicki can assess the safety and tolerability of APG-1387 as a single agent, including determination of the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs), when intravenously administered to patients with advanced solid tumors and hematologic malignancies.	
<u>University Employee; University Title; Relationship with Ascentage Pharma Group Corporation, Ltd.</u> <ul style="list-style-type: none">• Shaomeng Wang; Professor, Internal Medicine; Partial Owner	

Project #2

Amendment to Research Agreement between the University and Labyrinth Biotech Inc. Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
Title: Testing of inertial microfluidic device for cancer cell isolation	U-M Project ID: 22-PAF01983
Direct Sponsor: Labyrinth Biotech Inc.	
Principal Investigator/Department: Sunitha Nagraath, Chemical Engineering	
Agreement Initiated: March 2, 2021	
Current Project Duration: Two (2) Years Additional Time: One (1) Year	Current Funding Support: \$133,922 Additional Funding Support: \$95,926
Purpose: The purpose of this amendment to add additional funds and time so that Dr. Nagraath may continue to perform experiments to verify the recovery of the cancer cells and their purity of isolation from samples.	
<u>University Employee; University Title; Relationship with Labyrinth Biotech Inc.</u> <ul style="list-style-type: none">• Sunitha Nagraath; Professor, Chemical Engineering; Partial Owner	

Project #3

**Amendment to Subcontract Agreement between the University and May Mobility, Inc.
Reviewed by the UMOR Conflict of Interest Review Committee**

Project Information

Title: Inclusive Design Challenge-Phase I – Additional Task

U-M Project ID: 22-PAF02078

Direct Sponsor: May Mobility, Inc.

Prime Sponsor: Department of Transportation

Principal Investigator/Department: Kathleen Klinich, University of Michigan Transportation Research Institute-Biosciences Group (UMTRI)

Agreement Initiated: February 1, 2021

Current Project Duration: Thirteen (13) months
Additional Time: Four (4) months

Current Funding Support: \$116,000
Additional Funding Support: \$7,744

Purpose: The purpose of this amendment to add additional funds and time so that Dr. Klinich may perform an additional task related to wheelchair anchor design.

University Employee; University Title; Relationship with May Mobility, Inc.

- Edwin Olson; Professor, Electrical Engineering and Computer Science; Partial Owner

Project #4

**SBIR Phase I Subcontract Agreement between the University and MoxyTech, Inc.
Reviewed by the UMOR Conflict of Interest Review Committee**

Project Information

Title: 3D pain mobile technology with machine learning outcomes to increase diversity, inclusion, and accuracy in pain management of complex patients

U-M Project ID: 22-PAF01079

Direct Sponsor: MoxyTech, Inc.

Prime Sponsor: National Institutes of Health

Principal Investigator/Department: Alexandre DaSilva, Dentistry - Prosthodontics

Project Duration: Two (2) Years

Funding Support: \$182,484

Purpose: The purpose of this project is to develop multiple and interchangeable GeoPain 3D-body/face models that will address the unmet need of data diversity with extensive inclusion and engagement in pain management.

University Employee; University Title; Relationship with MoxyTech, Inc.

- Alexandre DaSilva; Associate Professor, Dentistry - Prosthodontics; Partial Owner

Project #5

**Research Agreement between the University and NS Nanotech Inc.
Reviewed by the UMOR Conflict of Interest Review Committee**

Project Information

Title: High Efficiency InGaN Nanowire Green and Red Micro-LEDs **U-M Project ID:** 22-PAF02012

Direct Sponsor: NS Nanotech Inc.

Principal Investigator/Department: Zetian Mi, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS-ECE) Division

Project Duration: One (1) Year **Funding Support:** \$975,000

Purpose: The purpose of this project is to develop high efficiency InGaN nanowire-based micro-LEDs operating in the deep visible (e.g., green and red) wavelengths.

University Employee; University Title; Relationship with NS Nanotech Inc.

- Zetian Mi; Professor, EECS-ECE Division; Partial Owner

Project #6

**Other Sponsored Activity between the University and PTM Therapeutics, Inc.
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: Tissue IHC Survey of GM35 Epitope Expression **U-M Project ID:** 21-PAF06473

Direct Sponsor: PTM Therapeutics, Inc.

Principal Investigator/Department: Jennifer Brazil, Pathology

Project Duration: One (1) Year **Funding Support:** \$28,934

Purpose: The purpose of this activity is to perform a tissue IHC survey of GM35 epitope expression on a variety of tissues.

University Employee; University Title; Relationship with PTM Therapeutics, Inc.

- Jennifer Brazil; Research Assistant Professor, Pathology; Partial Owner
- Charles Parkos; Professor, Pathology; Partial Owner

Project #7

**Other Sponsored Activity between the University and Rappta Therapeutics Oy
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: Characterizing role of novel PP2A activators in human cancer

U-M Project ID: 22-PAF01245

Direct Sponsor: Rappta Therapeutics Oy

Principal Investigator/Department: Goutham Narla, Internal Medicine-Genetic Medicine

Project Duration: Ten (10) Months

Funding Support: \$750,000

Purpose: The purpose of this activity is to test the effects of a series of small molecule activators of PP2A on a series of cancer cell lines.

University Employee; University Title; Relationship with Rappta Therapeutics Oy

- Goutham Narla; Professor, Internal Medicine-Genetic Medicine; Partial Owner

Project #8

**Other Sponsored Activity between the University and Xoran Technologies, LLC
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: Xoran Tech - Exec MBA 2021

U-M Project ID: 22-PAF01753

Co-Direct Sponsor: Xoran Technologies, LLC

Principal Investigator/Department: Gretchen Spreitzer, Ross School of Business-EXECMBA MAP Projects

Project Duration: One (1) Year

Funding Support: \$5,000

Purpose: The purpose of this activity is for Ross students to perform a project to recommend a growth strategy option that looks at the IPO process, strategic sale, or possible joint venture to maximize the value of the company.

University Employee; University Title; Relationship with Xoran Technologies, LLC

- Neal Clinthorne; Research Professor Emeritus, Radiology; Partial Owner